Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kiniksa’s Mavrilimumab Fails In Late-Stage COVID-19 Trial, Doubles Back On Arcalyst

Executive Summary

The firm’s anti GM-CSF candidate has underwhelmed in a study in hospitalized COVID-19 patients, triggering renewed focus on its recently launched product Arcalyst for recurrent pericarditis.

You may also be interested in...



Keeping Track: US FDA Approves J&J’s Novel MS Drug Ponvory, Breakthrough Pericarditis Claim For Kiniksa’s Arcalyst

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Nine Major Approval Decisions To Watch In Early 2022

Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.

Sanofi Pairs Up With Non-Profit Protas In Quest To Cut Clinical Trial Costs

The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel